PHASE II RANDOMIZED STUDY OF MAINTENANCE TREATMENT WITH BEVACIZUMAB OR BEVACIZUMAB PLUS METRONOMIC CHEMOTHERAPY AFTER FIRST-LINE INDUCTION FOLFOXIRI PLUS BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER PATIENTS

Trial Profile

PHASE II RANDOMIZED STUDY OF MAINTENANCE TREATMENT WITH BEVACIZUMAB OR BEVACIZUMAB PLUS METRONOMIC CHEMOTHERAPY AFTER FIRST-LINE INDUCTION FOLFOXIRI PLUS BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER PATIENTS

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Cyclophosphamide; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms MOMA
  • Most Recent Events

    • 24 May 2018 Results of an analysis validating loss of chromosome 18q11.2-q12.1, as the predictive factor for survival in patients with metastatic colorectal cancer treated with Bevacizumab using data from three additional multicenter cohorts (Angiopredict cohort, MOMA cohort and NoBev cohort), published in the Journal of Clinical Oncology.
    • 13 Mar 2018 Results of a pooled analysis of five prospective trials ((NCT00719797, NCT02271464, NCT02295930, EudraCT2008-001062-93 and NCT02086656; n=153) assessing prognostic impact of histopathologic parameters, published in the British Journal of Cancer
    • 06 Jun 2017 Results (n=482) of pooled analysis of TRIBE and MOMA studies presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top